For Report Sample Contact: neeraj@kuickresearch.com
Report Weblink: https://www.kuickresearch.com/report-global-peptide-antibiotics-market-and-clinical-pipeline-insight-2023.php
Table of Contents
1. Peptide Antibiotics – A New Era for Antibiotics
1.1 Introduction
1.2 Systemization of Peptide Antibiotics and Drugs
1.2.1 Non-Ribosomally Synthesized Peptide Antibiotics
1.2.2 Ribosomal Synthesized Peptide Antibiotics
2. Mechanism and Production of Peptide Antibiotics
2.1 Approach of Peptide Antibiotics on Bacterial Surface
2.2 Creational Process of Peptide Antibiotics
3. Identification of Human Antimicrobial Peptides
3.1 Human Defensins
3.2 Human Cathelicidins
3.3 Antimicrobial Neuropeptides
4. Portrayal of Peptide Antibiotics in Cancer Treatment
4.1 Introduction
4.2 Mechanism of Antimicrobial Peptides in Cancer Treatment
5. Categorization of Anticancer Peptides
5.1 Alpha-Helical Anticancer Peptides
5.2 Beta-Sheet Anticancer Peptides
6. Approved Peptide Antibiotics
6.1 Bacitracin
6.2 Viomycin
7. Market Analysis of Peptide Antibiotics
7.1 Introduction to Antibacterial Drug Market
7.2 Global Antimicrobial Peptide Market
8. Market Dynamics of Antimicrobial Peptides
8.1 Favorable Parameters
8.2 Challenges
9. Future Perspective of Peptide Antibiotics Market and Drug Development
10. Global Peptide Antibiotics Clinical Pipeline Overview
10.1 By Country
10.2 By Indication
10.3 By Mode of Action
10.4 By Formulation
10.5 By Delivery Route
11. Global Peptide Antibiotics Clinical Pipeline by Company, Indication and Phase
11.1 Research
11.2 Preclinical
11.3 Clinical
11.4 Phase-I
11.5 Phase-II
11.6 Phase-III
11.7 Preregistration
12. Marketed Peptide Antibiotics Clinical and Patent Analysis
12.1 Telavancin (Arbelic and Vibativ)
12.2 Dalbavancin (Dalvance and Xydalba)
12.3 Daptomycin Intravenous (Cubicin)
12.4 Oritavancin (Nuvocid and ORBACTIV)
12.5 Teicoplanin (Targocid)
12.6 Vancomycin (Vancomycin hydrochloride)
13. Competitive Landscape
13.1 AMP Therapeutics
13.2 Eli Lilly
13.3 GlaxoSmithKline
13.4 Hospira
13.5 Kasten
13.6 Madam Therapeutics
13.7 Novartis
13.8 Pacgen Life Science Corporation
13.9 Pfizer
13.10 Phosphagenics
13.11 Savara Pharmaceuticals
13.12 Theravance
13.13 Vicuron Pharmaceuticals
Figure 1-1: Structure of Some Important Peptide Antibiotics
Figure 1-2: Classification and Characterization of Peptide Antibiotics
Figure 2-1: Targets for Antimicrobial Peptides to Inhibit the Bacterial Growth
Figure 2-2: Chemical Structure of Teixobactin
Figure 2-3: Steps for the Solid Phase Synthesis of Teixobactin
Figure 3-1: Typical Processing of Cathelicidin Protein by Protease Enzymes
Figure 3-2: Mechanism of Antimicrobial Peptides in Defense against Pathogens
Figure 4-1: Angiogenesis Inhibition Mechanism of Action
Figure 6-1: Bacitracin – Mechanism of Action
Figure 7-1: Global – Antibacterial Drug Market (US$ Billion), 2016-2023
Figure 7-2: Usage of Therapeutic Peptides and Proteins in Different Disorders (%)
Figure 7-3: Global – Peptide Drug Market (US$ Billion), 2016-2023
Figure 7-4: Therapeutic Peptide Based Drugs over Route of Administration
Figure 7-5: Global – Peptide Antibiotics Clinical Pipeline by Phase (%), 2017 till 2023
Figure 7-6: Global – Peptide Antibiotics Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 8-1: Favorable Parameters which Helps in the Growth of Antimicrobial Peptide
Figure 8-2: Challenges to Antimicrobial Peptide Market Growth
Figure 9-1: Different Possible Treatment Options of Cancer by Using Peptides
Figure 10-1: Global – Peptide Antibiotics Clinical Pipeline by Country (%), 2017 till 2023
Figure 10-2: Global – Peptide Antibiotics Clinical Pipeline by Indication (%), 2017 till 2023
Figure 10-3: Global – Peptide Antibiotics Clinical Pipeline by Mode of Action (%), 2017 till 2023
Figure 10-4: Global – Peptide Antibiotics Clinical Pipeline by Formulation (%), 2017 till 2023
Figure 10-5: Global – Peptide Antibiotics Clinical Pipeline by Delivery Route (%), 2017 till 2023
Table 3-1: Cell Sources of Human Defensins Antimicrobial Peptides
Table 9-1: Future Human Antimicrobial Peptides and their Proposed Targets
